Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

By afschroeder • March 5, 2026

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol. 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.02.015. Epub ahead of print. PMID: 41780642.

Tags: burden of disease, endocrine resistance, Hematology/Oncology, metastatic breast cancer, Publications, subgroup analysis, time to progression, trastuzumab deruxtecan

Related Posts

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer

Swisher EM, Konecny G, Cohen J, Colon-Otero G, Danziger N, Lin DI, Li G, Quintanilha JCF, Decker B, Ross JS, Gearing M, Baker K, Scott[...]

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]